The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients

Critical Reviews in Oncology/Hematology

Volumn 95, Issue 2, 2015, Pages 179-190

  Monteverde, Martino ^a   Milano, Gerard ^b   Strola, Giuliana ^a   Maffi, Monica ^a   Lattanzio, Laura ^a   Vivenza, Daniela ^a   Tonissi, Federica ^a   Merlano, Marco ^a   Lo Nigro, Cristiana ^a  

^a S CROCE E CARLE HOSPITAL   (Italy)

^b CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

ADCC; Antitumor monoclonal antibody; Cellular immunity; Cetuximab; Natural Killer

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; INTERLEUKIN 2; PANITUMUMAB; TRASTUZUMAB; CANCER ANTIBODY; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER CELL LINE; CELL DEATH; CELL VIABILITY; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG TARGETING; EFFECTOR CELL; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; REVIEW; TARGET CELL; ANTAGONISTS AND INHIBITORS; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; NEOPLASMS; PATHOLOGY; PROCEDURES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CETUXIMAB; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84937515707     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2015.02.014     Document Type: Review

References (29)

1. Lòpez-Albaitero A., Ferris R.L. Immune activation by epidermal growth factor receptor-specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2007, 133:1277-1281.
2. Kondo N., Tsukuda M., Taguchi T., Nakazaki K., Sakakibara A., Takahashi H., et al. Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities. Cancer Sci 2011, 102(9):1717-1723. 10.1111/j.1349-7006.2011.01999.x.
3. Cascinu S., Berardi R., Salvagni S., Beretta G.D., Catalano V., Pucci F., et al. A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation. Br J Cancer 2008, 98:71-76.
4. Dechant M., Weisner W., Berger S., Peipp M., Beyer T., Schneider-Merck T., et al. Complement dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res 2008, 68(13):4998-5003. 10.1158/0008-5472.CAN-07-6226.
5. Imai K., Matsuyama S., Miyake S., Suga K., Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 2000, 356(9244):1795-1799.
6. Levy E.M., Roberti M.P., Mordoh J. Natural killer cells in human cancer: from biological functions to clinical applications. J Biomed Biotechnol 2011, 2011:676198. 10.1155/2011/676198.
7. Gerber D.E., Choy H. Cetuximab in combination therapy: from bench to clinic. Cancer Metastasis Rev 2010, 29(1):171-180. 10.1007/s10555-010-9215-6.
8. Vermorken J.B., Mesia R., Rivera F., Remenar E., Kawecki A., Rottey S. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359(11):1116-1127. 10.1056/NEJMoa0802656.
9. Prewett M.C., Hooper A.T., Bassi R., Ellis L.M., Waksal H.W., Hicklin D.J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumour xenografts. Clin Cancer Res 2002, 8:994-1003.
10. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010, 28(31):4697-4705. 10.1200/JCO.2009.27.4860.
11. Peeters M., Price T.J., Cervantes A., Sobrero A.F., Ducreux M., Hotko Y., et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010, 28(31):4706-4713. 10.1200/JCO.2009.27.6055.
12. Taylor R.J., Chan S.L., Wood A., Voskens C.J., Wolf J.S., Lin W., et al. FcgammaRIIIa polymorphisms and cetuximab induced cytotoxicity in squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2009, 58:997-1006.
13. López-Albaitero A., Lee S.C., Morgan S., Grandis J.R., Gooding W.E., Ferrone S., et al. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother 2009, 58:1853-1864.
14. Lee S.C., Srivastava R.M., López-Albaitero A., Ferrone S., Ferris R.L. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res 2011, 50:248-254.
15. Schneider-Merck T., Lammerts van Bueren J.J., Berger S., Rossen K., van Berkel P.H., Derer S., et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol 2010, 184:512-520.
16. Kawaguchi Y., Kono K., Mimura K., Sugai H., Akaike H., Fujii H. Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma. Int J Cancer 2006, 120:781-787.
17. Kimura H., Sakai K., Arao T., Shimoyama T., Tamura T., Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci 2007, 98(8):1275-1280.
18. Kurai J., Chikumi H., Hashimoto K., Yamaguchi K., Yamasaki A., Sako T., et al. Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 2007, 13:1552-1561.
19. Roda J.M., Joshi T., Butchar J.P., McAlees J.W., Lehman A., Tridandapani S., et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res 2007, 13(21):6419-6428.
20. Kawaguchi Y., Kono K., Mimura K., Mitsui F., Sugai H., Akaike H., et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 2007, 97:494-501.
21. Correale P., Marra M., Remondo C., Migali C., Misso G., Arcuri F.P., et al. Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC). Eur J Cancer 2010, 46:1703-1711.
22. Stephenson R.M., Lim C.M., Matthews M., Dietsch G., Hershberg R., Ferris R.L. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother 2013, 62:1347-1357. 10.1007/s00262-013-1437-3.
23. Broussas M., Broyer L., Goetsch L. Evaluation of antibody-dependent cell cytotoxicity using lactate dehydrogenase (LDH) measurement. Glycosylation engineering of biopharmaceuticals: methods and protocols. Methods Mol Biol 2013, 988:305-317.
24. Gioanni J., Fischel J.L., Lambert J.C., Demard F., Mazeau C., Zanghellini E., et al. Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment. Eur J Cancer Clin Oncol 1988, 24:1445-1455.
25. Lo Nigro C., Maffi M., Fischel J.L., Monteverde M., Catarsi P., Tonissi F., et al. Impact of erythropoietin on the effects of irradiation under hypoxia. J Cancer Res Clin Oncol 2009, 135:1615-1623. 10.1007/s00432-009-0609-1.
26. Grahn J.C., Isseroff R.R. Human melanocytes do not express EGF receptors. J Invest Dermatol 2004, 123(1):244-246.
27. Kan-Mitchell J., Mitchell M.S., Rao N., Liggett P.E. Characterization of uveal melanoma cell lines that grow as xenografts in rabbit eyes. Investig Ophthalmol Visual Sci 1989, 30(5):829-834.
28. Carmichael J., DeGraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 47(4):936-942.
29. Marabelle A., Kohrt H., Caux C., Levy R. Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res 2014, 20(7):1747-1756. 10.1158/1078-0432.CCR-13-2116.